Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Molecular and Cellular Biology / Genetics

Abstract LB-297: Metabolic alterations in plasma associated with survival in small cell lung cancer

Khyatiben V. Pathak, Se-Hoon Lee, Marissa McGilvrey, Krystine Mansfield, Derek Cridebring, Denise J. Roe, Timothy G. Whitsett, Keunchil Park and Patrick Pirrotte
Khyatiben V. Pathak
1Collaborative Center for Translational Mass Spectrometry, The Translational Genomics Research Institute, Phoenix, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Se-Hoon Lee
2Department of Medicine, Samsung Medical Center, Seoul, Republic of Korea;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marissa McGilvrey
1Collaborative Center for Translational Mass Spectrometry, The Translational Genomics Research Institute, Phoenix, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krystine Mansfield
1Collaborative Center for Translational Mass Spectrometry, The Translational Genomics Research Institute, Phoenix, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derek Cridebring
3Molecular Medicine Division, The Translational Genomics Research Institute, Phoenix, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denise J. Roe
4Mel and Enid Zuckerman College of Public Health, The University of Arizona Cancer Center, University of Arizona, Tucson, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy G. Whitsett
5The Translational Genomics Research Institute, Phoenix, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keunchil Park
2Department of Medicine, Samsung Medical Center, Seoul, Republic of Korea;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Pirrotte
1Collaborative Center for Translational Mass Spectrometry, The Translational Genomics Research Institute, Phoenix, AZ;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2019-LB-297 Published July 2019
  • Article
  • Info & Metrics
Loading
Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA

Abstract

Small cell lung cancer (SCLC) is an aggressive histological subset of lung cancer accounting for ~15% of diagnosed lung cancers (more than 230,000 patients in the US in 2018). Five-year survival rates for advanced SCLC are below 10% with a 2% 5-year survival rate for distant metastatic disease. The dismal survival rates are governed by a lack of targetable oncogenic mutations, a lack of therapeutic avenues, diagnosis at advanced (metastatic) stage, and expected therapeutic resistance to standard-of-care therapies. There is an unmet clinical need to identify new therapeutic avenues for SCLC and develop factors that would impact prognosis and predict therapeutic response. Circulating metabolites are functional surrogates for cellular phenotypes, making them ideal to study in cellular transformation and tumor progression. We hypothesize that alterations in cellular metabolism will correlate with patient prognosis and therapeutic response/resistance in SCLC. The clinical cohort was comprised of 27 SCLC patients treated at Samsung Medical Center, Seoul, South Korea. Of these, 15 patients were diagnosed with extensive disease, while 10 patients were detected with limited and 2 patients with intermediate disease. All of the patients were treated with platinum-based cytotoxic chemotherapy regimens. The plasma samples were collected at three stages, before treatment (baseline), six-weeks post treatment, and at clinical relapse. We employed targeted, quantitative metabolomics to query the plasma metabolome of the SCLC patients. The results describe comparisons of baseline and six-week post treatment samples with clinical outcomes. In this SCLC cohort the mutational profile (prevalent mutations in RB1 and TP53) was consistent with other SCLC datasets, although this set tended to have higher incidence of BRCA1/2 mutations. At the baseline measurement, plasma concentrations of 5 acylcarnitines including C14:2, C10:1, C12, C12:1, C14:1-OH and a lysoglycerophosphocholine (lysoPC a C16:1) were significantly associated with progression-free survival (PFS); while proline and acyl carnitine C10:1 were significantly associated with overall survival (OS) across the cohort. When comparing those patients who progressed rapidly on platinum-based therapy (< 93 days) to those that progressed more slowly (> 236 days), two sphingolipids (SM C24:1, SM C20:2) and asymmetric dimethylarginine (ADMA) were significantly increased in those patients progressing more rapidly. In looking at the metabolic alterations across 6-weeks of therapeutic exposure, we saw 5 glycerophospholipids were significantly lower (FDR adjusted p < 0.05). In exploratory analyses (unadjusted p < 0.05), plasma levels of 43 lipids including 31 glycerophospholipids, 7 sphingolipids, 5 acylcarnitines were increased. Overall, exposure to chemotherapy was associated with altered plasma lipid levels. The higher circulating acylcarnitines may indicate modulation of carnitine palmitoyltransferase and suppression of the beta-oxidation process. Thus, changes in the plasma metabolome may be associated with OS and PFS in SCLC, and indicative of rapid recurrence on standard therapies. A larger investigation of the plasma metabolome in SCLC may identify biomarkers of patient prognosis and/or therapeutic response/resistance, necessary advancements towards abating the dismal patient survival rates in this disease.

Citation Format: Khyatiben V. Pathak, Se-Hoon Lee, Marissa McGilvrey, Krystine Mansfield, Derek Cridebring, Denise J. Roe, Timothy G. Whitsett, Keunchil Park, Patrick Pirrotte. Metabolic alterations in plasma associated with survival in small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-297.

  • ©2019 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 79 (13 Supplement)
July 2019
Volume 79, Issue 13 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract LB-297: Metabolic alterations in plasma associated with survival in small cell lung cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract LB-297: Metabolic alterations in plasma associated with survival in small cell lung cancer
Khyatiben V. Pathak, Se-Hoon Lee, Marissa McGilvrey, Krystine Mansfield, Derek Cridebring, Denise J. Roe, Timothy G. Whitsett, Keunchil Park and Patrick Pirrotte
Cancer Res July 1 2019 (79) (13 Supplement) LB-297; DOI: 10.1158/1538-7445.AM2019-LB-297

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract LB-297: Metabolic alterations in plasma associated with survival in small cell lung cancer
Khyatiben V. Pathak, Se-Hoon Lee, Marissa McGilvrey, Krystine Mansfield, Derek Cridebring, Denise J. Roe, Timothy G. Whitsett, Keunchil Park and Patrick Pirrotte
Cancer Res July 1 2019 (79) (13 Supplement) LB-297; DOI: 10.1158/1538-7445.AM2019-LB-297
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Molecular and Cellular Biology / Genetics

  • Abstract 4772: Metabolic programming of bladder cancer: Vulnerabilities and opportunities
  • Abstract 4820: Novel protein AX-295aa encoded by circAX promotes gastric carcinogenesis by activating Wnt pathway
  • Abstract 5924: A clock gene of TIM promotes colorectal cancer tumorigenesis through binding with myosin-9
Show more Molecular and Cellular Biology / Genetics

Poster Presentations - Late-Breaking Abstracts

  • Abstract LB-319: Establishment of automated multiplex immunofluorescence T-cell panel for baseline screening of syngeneic mouse models and evaluation of T-cell infiltration in A20 syngeneic tumors treated with TAK-981, a first-in-class SUMO inhibitor
  • Abstract LB-306: Long non-coding RNA NEAT1 promotes lung metastasis of soft tissue sarcoma by regulating RNA splicing pathways
  • Abstract LB-323: Atrx deletion delays tumor formation and increases radiosensitivity of a primary mouse model of soft tissue sarcoma
Show more Poster Presentations - Late-Breaking Abstracts

Poster Presentations - Late-Breaking Research: Molecular and Cellular Biology / Genetics

  • Abstract LB-319: Establishment of automated multiplex immunofluorescence T-cell panel for baseline screening of syngeneic mouse models and evaluation of T-cell infiltration in A20 syngeneic tumors treated with TAK-981, a first-in-class SUMO inhibitor
  • Abstract LB-306: Long non-coding RNA NEAT1 promotes lung metastasis of soft tissue sarcoma by regulating RNA splicing pathways
  • Abstract LB-323: Atrx deletion delays tumor formation and increases radiosensitivity of a primary mouse model of soft tissue sarcoma
Show more Poster Presentations - Late-Breaking Research: Molecular and Cellular Biology / Genetics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement